Drug Detail

Drug Name Olaparib
Trade Name Lynparza
Synonyms AZD2281|KU-0059436
Drug Descriptions

Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer, germline BRCA-mutated and ERBB2 (HER2)-negative breast cancer, and advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations (FDA.gov).

DrugClasses PARP Inhibitor (Pan) 17

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Cediranib + Olaparib
Olaparib + Temozolomide + SN-38
Olaparib + Trabectedin
Bevacizumab + Carboplatin + Pembrolizumab + Olaparib
Olaparib + Cetuximab
BGJ398 + Olaparib
AZD6738 + Olaparib
CRLX101 + Olaparib
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
Dinaciclib + Olaparib
Olaparib Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for use in patients with germline BRCA-mutated advanced ovarian cancer, germline BRCA-mutated and ERBB2 (HER2)-negative breast cancer, and advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutations (FDA.gov).
Olaparib + Valproic Acid
Olaparib + Vistusertib
Cediranib + Durvalumab + Olaparib
Abiraterone + Olaparib
Olaparib + Onalespib
AZD6482 + Olaparib
Olaparib + Ramucirumab
BPTES + Olaparib
Fulvestrant + Olaparib + Palbociclib
Olaparib + Paclitaxel + Pembrolizumab
Bevacizumab + Durvalumab + Olaparib
Carboplatin + Olaparib
Olaparib + Irinotecan
Olaparib + Pembrolizumab
Olaparib + VE-821
Fludarabine + Olaparib
BGB-324 + Olaparib
Olaparib + Vorinostat
BKM120 + Olaparib
Olaparib + Everolimus
Olaparib + Prexasertib
CCT241533 + Olaparib
Olaparib + Trametinib
AZD5363 + Olaparib
Olaparib + Sapacitabine
Bevacizumab + Olaparib + Paclitaxel + Pembrolizumab
CB-839 + Olaparib
Olaparib + YU238259
Cisplatin + Paclitaxel + Bevacizumab + Olaparib
Olaparib + Paclitaxel
Olaparib + Testosterone Enanthate
Carboplatin + Pembrolizumab + Olaparib
Durvalumab + Olaparib
AGI-5198 + Olaparib
BYL719 + Olaparib
Olaparib + Selumetinib
Olaparib + KU-0063794
MEDI4736 + Olaparib + Tremelimumab
Abiraterone + Prednisone + Olaparib
Olaparib + SN-38
Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
MK-1775 + Olaparib
Olaparib + Temozolomide
Bendamustine + Olaparib
Olaparib + TP-0903
Camptothecin + Olaparib
Olaparib + Cisplatin